Phenazopyridine Hydrochloride
Loading...Phenazopyridine Hydrochloride Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
Phenazopyridine hydrochloride is reasonably anticipated to be a human carcinogen based on sufficient evidence of carcinogenicity in experimental animals (IARC 1980, 1982, 1987, NCI 1978). When administered in the diet, phenazopyridine hydrochloride increased the incidences of hepatocellular adenomas and carcinomas in female mice and adenomas and adenocarcinomas of the colon and rectum in rats of both sexes.
There is inadequate evidence for the carcinogenicity of phenazopyridine hydrochloride in humans (IARC 1987). In one limited epidemiological study, no significant excess of any cancer was observed among 2,214 patients who received phenazopyridine hydrochloride and were followed for a minimum of 3 years.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
Phenazopyridine HCl is indicated for the symptomatic relief of pain, burning, urgency frequency, and other discomforts arising from irritation of the mucosa of the lower urinary tract caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters.
The use of phenazopyridine for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. The drug should be used for symptomatic relief of pain and not as a substitute for specific surgery or antimicrobial therapy.
Phenazopyridine is compatible with antimicrobial therapy and can help relieve pain and discomfort during the interval before antimicrobial therapy controls the infection.
Treatment of a urinary tract infection with phenazopyridine should not exceed 2 days. There is no evidence that the combined administration of phenazopyridine and an antimicrobial provides greater benefit than administration of the antimicrobial alone after 2 days. (See DOSAGE AND ADMINISTRATION.)
History
There is currently no drug history available for this drug.
Other Information
Phenazopyridine Hydrochloride is a reddish-brown, odorless, slightly bitter, crystalline powder. It has a specific local analgesic effect in the urinary tract, promptly relieving burning and pain.
Following is the structural formula:
Phenazopyridine HCl tablets contain the following inactive ingredients: Croscarmellose sodium, magnesium stearate, maize (corn) starch, microcrystalline cellulose, pregelatinized starch, polyvinylpyrrolidone (PVP), silicon dioxide.
Sources
Phenazopyridine Hydrochloride Manufacturers
-
Remedyrepack Inc.
![Phenazopyridine Hydrochloride Tablet [Remedyrepack Inc. ]](/wp-content/themes/bootstrap/assets/img/loading2.gif)
Phenazopyridine Hydrochloride | Remedyrepack Inc.
Adults: 200 mg 3 times daily after meals. When used concomitantly with an antibacterial agent for the treatment of a urinary tract infection, the administration of phenazopyridine should not exceed 2 days. If symptoms persist, the patient should be re-evaluated.
-
Proficient Rx Lp
Phenazopyridine Hydrochloride | Proficient Rx Lp
Adults: 200 mg 3 times daily after meals. When used concomitantly with an antibacterial agent for the treatment of a urinary tract infection, the administration of phenazopyridine should not exceed 2 days. If symptoms persist, the patient should be re-evaluated.
-
Eci Pharmaceuticals, Llc
Phenazopyridine Hydrochloride | Upsher-smith Laboratories, Inc.
Divalproex sodium delayed-release tablets are intended for oral administration. Divalproex sodium delayed-release tablets should be swallowed whole and should not be crushed or chewed.
Patients should be informed to take divalproex sodium delayed-release tablets every day as prescribed. If a dose is missed it should be taken as soon as possible, unless it is almost time for the next dose. If a dose is skipped, the patient should not double the next dose.
2.1 ManiaDivalproex sodium delayed-release tablets are administered orally. The recommended initial dose is 750 mg daily in divided doses. The dose should be increased as rapidly as possible to achieve the lowest therapeutic dose which produces the desired clinical effect or the desired range of plasma concentrations. In placebo-controlled clinical trials of acute mania, patients were dosed to a clinical response with a trough plasma concentration between 50 and 125 mcg/mL. Maximum concentrations were generally achieved within 14 days. The maximum recommended dosage is 60 mg/kg/day.
There is no body of evidence available from controlled trials to guide a clinician in the longer term management of a patient who improves during divalproex sodium delayed-release tablets treatment of an acute manic episode. While it is generally agreed that pharmacological treatment beyond an acute response in mania is desirable, both for maintenance of the initial response and for prevention of new manic episodes, there are no data to support the benefits of divalproex sodium delayed-release tablets in such longer-term treatment. Although there are no efficacy data that specifically address longer-term antimanic treatment with divalproex sodium delayed-release tablets, the safety of divalproex sodium delayed-release tablets in long-term use is supported by data from record reviews involving approximately 360 patients treated with divalproex sodium delayed-release tablets for greater than 3 months.
2.2 EpilepsyDivalproex sodium delayed-release tablets are administered orally. Divalproex sodium delayed-release tablets are indicated as monotherapy and adjunctive therapy in complex partial seizures in adults and pediatric patients down to the age of 10 years, and in simple and complex absence seizures. As the divalproex sodium delayed-release tablets dosage is titrated upward, concentrations of clonazepam, diazepam, ethosuximide, lamotrigine, tolbutamide, phenobarbital, carbamazepine, and/or phenytoin may be affected [see Drug Interactions (7.2)].
Complex Partial Seizures
For adults and children 10 years of age or older.
Monotherapy (Initial Therapy)
Divalproex sodium delayed-release tablets have not been systematically studied as initial therapy. Patients should initiate therapy at 10 to 15 mg/kg/day. The dosage should be increased by 5 to 10 mg/kg/week to achieve optimal clinical response. Ordinarily, optimal clinical response is achieved at daily doses below 60 mg/kg/day. If satisfactory clinical response has not been achieved, plasma levels should be measured to determine whether or not they are in the usually accepted therapeutic range (50 to 100 mcg/mL). No recommendation regarding the safety of valproate for use at doses above 60 mg/kg/day can be made.
The probability of thrombocytopenia increases significantly at total trough valproate plasma concentrations above 110 mcg/mL in females and 135 mcg/mL in males. The benefit of improved seizure control with higher doses should be weighed against the possibility of a greater incidence of adverse reactions.
Conversion to Monotherapy
Patients should initiate therapy at 10 to 15 mg/kg/day. The dosage should be increased by 5 to 10 mg/kg/week to achieve optimal clinical response. Ordinarily, optimal clinical response is achieved at daily doses below 60 mg/kg/day. If satisfactory clinical response has not been achieved, plasma levels should be measured to determine whether or not they are in the usually accepted therapeutic range (50-100 mcg/mL). No recommendation regarding the safety of valproate for use at doses above 60 mg/kg/day can be made. Concomitant antiepilepsy drug (AED) dosage can ordinarily be reduced by approximately 25% every 2 weeks. This reduction may be started at initiation of divalproex sodium delayed-release tablets therapy, or delayed by 1 to 2 weeks if there is a concern that seizures are likely to occur with a reduction. The speed and duration of withdrawal of the concomitant AED can be highly variable, and patients should be monitored closely during this period for increased seizure frequency.
Adjunctive Therapy
Divalproex sodium delayed-release tablets may be added to the patient's regimen at a dosage of 10 to 15 mg/kg/day. The dosage may be increased by 5 to 10 mg/kg/week to achieve optimal clinical response. Ordinarily, optimal clinical response is achieved at daily doses below 60 mg/kg/day. If satisfactory clinical response has not been achieved, plasma levels should be measured to determine whether or not they are in the usually accepted therapeutic range (50 to 100 mcg/mL). No recommendation regarding the safety of valproate for use at doses above 60 mg/kg/day can be made. If the total daily dose exceeds 250 mg, it should be given in divided doses.
In a study of adjunctive therapy for complex partial seizures in which patients were receiving either carbamazepine or phenytoin in addition to valproate, no adjustment of carbamazepine or phenytoin dosage was needed [see Clinical Studies (14.2)]. However, since valproate may interact with these or other concurrently administered AEDs as well as other drugs, periodic plasma concentration determinations of concomitant AEDs are recommended during the early course of therapy [see Drug Interactions (7)].
Simple and Complex Absence Seizures
The recommended initial dose is 15 mg/kg/day, increasing at one week intervals by 5 to 10 mg/kg/day until seizures are controlled or side effects preclude further increases. The maximum recommended dosage is 60 mg/kg/day. If the total daily dose exceeds 250 mg, it should be given in divided doses.
A good correlation has not been established between daily dose, serum concentrations, and therapeutic effect. However, therapeutic valproate serum concentrations for most patients with absence seizures is considered to range from 50 to 100 mcg/mL. Some patients may be controlled with lower or higher serum concentrations [see Clinical Pharmacology (12.3)].
As the divalproex sodium delayed-release tablets dosage is titrated upward, blood concentrations of phenobarbital and/or phenytoin may be affected [see Drug Interactions (7.2)].
Antiepilepsy drugs should not be abruptly discontinued in patients in whom the drug is administered to prevent major seizures because of the strong possibility of precipitating status epilepticus with attendant hypoxia and threat to life.
In epileptic patients previously receiving valproic acid therapy, divalproex sodium delayed-release tablets should be initiated at the same daily dose and dosing schedule. After the patient is stabilized on divalproex sodium delayed-release tablets, a dosing schedule of two or three times a day may be elected in selected patients.
2.3 MigraineDivalproex Sodium Delayed-Release Tablets are indicated for prophylaxis of migraine headaches in adults.
Divalproex sodium delayed-release tablets are administered orally. The recommended starting dose is 250 mg twice daily. Some patients may benefit from doses up to 1,000 mg/day. In the clinical trials, there was no evidence that higher doses led to greater efficacy.
2.4 General Dosing AdviceDosing in Elderly Patients
Due to a decrease in unbound clearance of valproate and possibly a greater sensitivity to somnolence in the elderly, the starting dose should be reduced in these patients. Dosage should be increased more slowly and with regular monitoring for fluid and nutritional intake, dehydration, somnolence, and other adverse reactions. Dose reductions or discontinuation of valproate should be considered in patients with decreased food or fluid intake and in patients with excessive somnolence. The ultimate therapeutic dose should be achieved on the basis of both tolerability and clinical response [see Warnings and Precautions (5.14), Use in Specific Populations (8.5) and Clinical Pharmacology (12.3)].
Dose-Related Adverse Reactions
The frequency of adverse effects (particularly elevated liver enzymes and thrombocytopenia) may be dose-related. The probability of thrombocytopenia appears to increase significantly at total valproate concentrations of ≥ 110 mcg/mL (females) or ≥ 135 mcg/mL (males) [see Warnings and Precautions (5.8)]. The benefit of improved therapeutic effect with higher doses should be weighed against the possibility of a greater incidence of adverse reactions.
G.I. Irritation
Patients who experience G.I. irritation may benefit from administration of the drug with food or by slowly building up the dose from an initial low level.
-
Acella Pharmaceuticals, Llc
Phenazopyridine Hydrochloride | Acella Pharmaceuticals, Llc
Adults: 200 mg 3 times daily after meals. When used concomitantly with an antibacterial agent for the treatment of a urinary tract infection, the administration of phenazopyridine should not exceed 2 days. If symptoms persist, the patient should be re-evaluated.
-
Remedyrepack Inc.
Phenazopyridine Hydrochloride | Remedyrepack Inc.
100 mg Tablets: Average adult dosage is two tablets 3 times a day after meals.
200 mg Tablets: Average adult dosage is one tablet 3 times a day after meals.
When used concomitantly with an antibacterial agent for the treatment of a urinary tract infection, the administration of Phenazopyridine HCl should not exceed 2 days.
-
Remedyrepack Inc.
Phenazopyridine Hydrochloride | Remedyrepack Inc.
100 mg Tablets: Average adult dosage is two tablets 3 times a day after meals.
200 mg Tablets: Average adult dosage is one tablet 3 times a day after meals.
When used concomitantly with an antibacterial agent for the treatment of a urinary tract infection, the administration of Phenazopyridine HCl should not exceed 2 days.
-
Blenheim Pharmacal, Inc.
Phenazopyridine Hydrochloride | Blenheim Pharmacal, Inc.
100 mg Tablets: Average adult dosage is two tablets 3 times a day after meals.
200 mg Tablets: Average adult dosage is one tablet 3 times a day after meals.
When used concomitantly with an antibacterial agent for the treatment of a urinary tract infection, the administration of Phenazopyridine HCl should not exceed 2 days.
-
A-s Medication Solutions Llc
Phenazopyridine Hydrochloride | A-s Medication Solutions Llc
100 mg Tablets: Average adult dosage is two tablets 3 times a day after meals.
200 mg Tablets: Average adult dosage is one tablet 3 times a day after meals.
When used concomitantly with an antibacterial agent for the treatment of a urinary tract infection, the administration of Phenazopyridine HCl should not exceed 2 days.
-
A-s Medication Solutions Llc
Phenazopyridine Hydrochloride | A-s Medication Solutions Llc
100 mg Tablets: Average adult dosage is two tablets 3 times a day after meals.
200 mg Tablets: Average adult dosage is one tablet 3 times a day after meals.
When used concomitantly with an antibacterial agent for the treatment of a urinary tract infection, the administration of Phenazopyridine HCl should not exceed 2 days.
-
Remedyrepack Inc.
Phenazopyridine Hydrochloride | Remedyrepack Inc.
100 mg Tablets: Average adult dosage is two tablets 3 times a day after meals.
200 mg Tablets: Average adult dosage is one tablet 3 times a day after meals.
When used concomitantly with an antibacterial agent for the treatment of a urinary tract infection, the administration of Phenazopyridine HCl should not exceed 2 days.
-
Proficient Rx Lp
Phenazopyridine Hydrochloride | Proficient Rx Lp
100 mg Tablets: Average adult dosage is two tablets 3 times a day after meals.
200 mg Tablets: Average adult dosage is one tablet 3 times a day after meals.
When used concomitantly with an antibacterial agent for the treatment of a urinary tract infection, the administration of Phenazopyridine HCl should not exceed 2 days.
-
Eci Pharmaceuticals, Llc
Phenazopyridine Hydrochloride | Eci Pharmaceuticals, Llc
100 mg Tablets: Average adult dosage is two tablets 3 times a day after meals.
200 mg Tablets: Average adult dosage is one tablet 3 times a day after meals.
When used concomitantly with an antibacterial agent for the treatment of a urinary tract infection, the administration of Phenazopyridine HCl should not exceed 2 days.
-
Amneal Pharmaceuticals
Phenazopyridine Hydrochloride | Amneal Pharmaceuticals
100 mg Tablets: Average adult dosage is two tablets 3 times a day after meals.
200 mg Tablets: Average adult dosage is one tablet 3 times a day after meals.
When used concomitantly with an antibacterial agent for the treatment of a urinary tract infection, the administration of Phenazopyridine HCl should not exceed 2 days.
-
Rebel Distributors Corp
Phenazopyridine Hydrochloride | Rebel Distributors Corp
100 mg Tablets: Average adult dosage is two tablets 3 times a day after meals.
200 mg Tablets: Average adult dosage is one tablet 3 times a day after meals.
When used concomitantly with an antibacterial agent for the treatment of a urinary tract infection, the administration of Phenazopyridine HCl should not exceed 2 days.
-
Medvantx, Inc.
Phenazopyridine Hydrochloride | Medvantx, Inc.
100 mg Tablets: Average adult dosage is two tablets 3 times a day after meals.
200 mg Tablets: Average adult dosage is one tablet 3 times a day after meals.
When used concomitantly with an antibacterial agent for the treatment of a urinary tract infection, the administration of Phenazopyridine HCl should not exceed 2 days.
-
Unit Dose Services
Phenazopyridine Hydrochloride | Unit Dose Services
100 mg Tablets: Average adult dosage is two tablets 3 times a day after meals.
200 mg Tablets: Average adult dosage is one tablet 3 times a day after meals.
When used concomitantly with an antibacterial agent for the treatment of a urinary tract infection, the administration of Phenazopyridine HCl should not exceed 2 days.
-
Bryant Ranch Prepack
Phenazopyridine Hydrochloride | Bryant Ranch Prepack
100 mg Tablets: Average adult dosage is two tablets 3 times a day after meals.
200 mg Tablets: Average adult dosage is one tablet 3 times a day after meals.
When used concomitantly with an antibacterial agent for the treatment of a urinary tract infection, the administration of Phenazopyridine HCl should not exceed 2 days.
-
American Health Packaging
Phenazopyridine Hydrochloride | American Health Packaging
100 mg Tablets: Average adult dosage is two tablets 3 times a day after meals.
200 mg Tablets: Average adult dosage is one tablet 3 times a day after meals.
When used concomitantly with an antibacterial agent for the treatment of a urinary tract infection, the administration of Phenazopyridine HCl should not exceed 2 days.
-
Clinical Solutions Wholesale
Phenazopyridine Hydrochloride | Clinical Solutions Wholesale
100 mg Tablets: Average adult dosage is two tablets 3 times a day after meals.
200 mg Tablets: Average adult dosage is one tablet 3 times a day after meals.
When used concomitantly with an antibacterial agent for the treatment of a urinary tract infection, the administration of Phenazopyridine HCl should not exceed 2 days.
-
Clinical Solutions Wholesale
Phenazopyridine Hydrochloride | Clinical Solutions Wholesale
100 mg Tablets: Average adult dosage is two tablets 3 times a day after meals.
200 mg Tablets: Average adult dosage is one tablet 3 times a day after meals.
When used concomitantly with an antibacterial agent for the treatment of a urinary tract infection, the administration of Phenazopyridine HCl should not exceed 2 days.
-
Liberty Pharmaceuticals, Inc.
Phenazopyridine Hydrochloride | Liberty Pharmaceuticals, Inc.
100 mg Tablets: Average adult dosage is two tablets 3 times a day after meals.
200 mg Tablets: Average adult dosage is one tablet 3 times a day after meals.
When used concomitantly with an antibacterial agent for the treatment of a urinary tract infection, the administration of Phenazopyridine HCl should not exceed 2 days.
-
Eci Pharmaceuticals, Llc
Phenazopyridine Hydrochloride | Eci Pharmaceuticals, Llc
100 mg Tablets: Average adult dosage is two tablets 3 times a day after meals.
200 mg Tablets: Average adult dosage is one tablet 3 times a day after meals.
When used concomitantly with an antibacterial agent for the treatment of a urinary tract infection, the administration of Phenazopyridine HCl should not exceed 2 days.
-
Aidarex Pharmaceuticals Llc
Phenazopyridine Hydrochloride | Aidarex Pharmaceuticals Llc
100 mg Tablets: Average adult dosage is two tablets 3 times a day after meals.
200 mg Tablets: Average adult dosage is one tablet 3 times a day after meals.
When used concomitantly with an antibacterial agent for the treatment of a urinary tract infection, the administration of Phenazopyridine HCl should not exceed 2 days.
-
Nationwide Laboratories, Llc
Phenazopyridine Hydrochloride | Nationwide Laboratories, Llc
100 mg Tablets: Average adult dosage is two tablets 3 times a day after meals.
200 mg Tablets: Average adult dosage is one tablet 3 times a day after meals.
When used concomitantly with an antibacterial agent for the treatment of a urinary tract infection, the administration of Phenazopyridine HCl should not exceed 2 days.
-
Preferred Pharmaceuticals, Inc.
Phenazopyridine Hydrochloride | Preferred Pharmaceuticals, Inc.
100 mg Tablets: Average adult dosage is two tablets 3 times a day after meals.
200 mg Tablets: Average adult dosage is one tablet 3 times a day after meals.
When used concomitantly with an antibacterial agent for the treatment of a urinary tract infection, the administration of Phenazopyridine HCl should not exceed 2 days.
-
Direct Rx
Phenazopyridine Hydrochloride | Direct Rx
100 mg Tablets: Average adult dosage is two tablets 3 times a day after meals.
200 mg Tablets: Average adult dosage is one tablet 3 times a day after meals.
When used concomitantly with an antibacterial agent for the treatment of a urinary tract infection, the administration of Phenazopyridine HCl should not exceed 2 days.
-
Avkare, Inc.
Phenazopyridine Hydrochloride | Avkare, Inc.
100 mg Tablets: Average adult dosage is two tablets 3 times a day after meals.
200 mg Tablets: Average adult dosage is one tablet 3 times a day after meals.
When used concomitantly with an antibacterial agent for the treatment of a urinary tract infection, the administration of Phenazopyridine HCl should not exceed 2 days.
-
Readymeds
Phenazopyridine Hydrochloride | Readymeds
100 mg Tablets: Average adult dosage is two tablets 3 times a day after meals.
200 mg Tablets: Average adult dosage is one tablet 3 times a day after meals.
When used concomitantly with an antibacterial agent for the treatment of a urinary tract infection, the administration of Phenazopyridine HCl should not exceed 2 days.
-
Cardinal Health
Phenazopyridine Hydrochloride | Cardinal Health
100 mg Tablets: Average adult dosage is two tablets 3 times a day after meals.
200 mg Tablets: Average adult dosage is one tablet 3 times a day after meals.
When used concomitantly with an antibacterial agent for the treatment of a urinary tract infection, the administration of Phenazopyridine HCl should not exceed 2 days.
-
Lake Erie Medical Dba Quality Care Products Llc
Phenazopyridine Hydrochloride | Lake Erie Medical Dba Quality Care Products Llc
100 mg Tablets: Average adult dosage is two tablets 3 times a day after meals.
200 mg Tablets: Average adult dosage is one tablet 3 times a day after meals.
When used concomitantly with an antibacterial agent for the treatment of a urinary tract infection, the administration of Phenazopyridine HCl should not exceed 2 days.
-
Northwind Pharmaceuticals
Phenazopyridine Hydrochloride | Northwind Pharmaceuticals
200 mg Tablets: Average adult dosage is one tablet 3 times a day after meals.
When used concomitantly with an antibacterial agent for the treatment of a urinary tract infection, the administration of Phenazopyridine HCl should not exceed 2 days.
-
Carilion Materials Management
Phenazopyridine Hydrochloride | Carilion Materials Management
100 mg Tablets: Average adult dosage is two tablets 3 times a day after meals.
200 mg Tablets: Average adult dosage is one tablet 3 times a day after meals.
When used concomitantly with an antibacterial agent for the treatment of a urinary tract infection, the administration of Phenazopyridine HCl should not exceed 2 days.
-
A-s Medication Solutions Llc
Phenazopyridine Hydrochloride | A-s Medication Solutions Llc
100 mg Tablets: Average adult dosage is two tablets 3 times a day after meals.
200 mg Tablets: Average adult dosage is one tablet 3 times a day after meals.
When used concomitantly with an antibacterial agent for the treatment of a urinary tract infection, the administration of Phenazopyridine HCl should not exceed 2 days.
-
Northwind Pharmaceuticals, Llc
Phenazopyridine Hydrochloride | Northwind Pharmaceuticals, Llc
100 mg Tablets: Average adult dosage is two tablets 3 times a day after meals.
200 mg Tablets: Average adult dosage is one tablet 3 times a day after meals.
When used concomitantly with an antibacterial agent for the treatment of a urinary tract infection, the administration of Phenazopyridine HCl should not exceed 2 days.
-
Remedyrepack Inc.
Phenazopyridine Hydrochloride | Remedyrepack Inc.
100 mg Tablets: Average adult dosage is two tablets 3 times a day after meals.
200 mg Tablets: Average adult dosage is one tablet 3 times a day after meals.
When used concomitantly with an antibacterial agent for the treatment of a urinary tract infection, the administration of Phenazopyridine HCl should not exceed 2 days.
-
Remedyrepack Inc.
Phenazopyridine Hydrochloride | Remedyrepack Inc.
100 mg Tablets: Average adult dosage is two tablets 3 times a day after meals.
200 mg Tablets: Average adult dosage is one tablet 3 times a day after meals.
When used concomitantly with an antibacterial agent for the treatment of a urinary tract infection, the administration of Phenazopyridine HCl should not exceed 2 days.
-
Remedyrepack Inc.
Phenazopyridine Hydrochloride | Remedyrepack Inc.
Adults: 200 mg 3 times daily after meals. When used concomitantly with an antibacterial agent for the treatment of a urinary tract infection, the administration of phenazopyridine should not exceed 2 days. If symptoms persist, the patient should be re-evaluated.
-
Remedyrepack Inc.
Phenazopyridine Hydrochloride | Remedyrepack Inc.
Adults: 200 mg 3 times daily after meals. When used concomitantly with an antibacterial agent for the treatment of a urinary tract infection, the administration of phenazopyridine should not exceed 2 days. If symptoms persist, the patient should be re-evaluated.
![Phenazopyridine Hydrochloride Tablet [Proficient Rx Lp]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5f965657-9b56-455f-af5e-23a8a9da9f81&name=802-label.jpg)
![Phenazopyridine Hydrochloride (Phenazopyridine) Tablet [Eci Pharmaceuticals, Llc]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=02304a23-4a5f-47bc-9687-4044b43f7a20&name=divalproex-06.jpg)
![Phenazopyridine Hydrochloride (Phenazopyridine Hydrochloride) Tablet Phenazopyridine Hydrochloride (Phenazopyridine Hydrochloride) Tablet [Acella Pharmaceuticals, Llc]](http://www.recallguide.org/wp-content/themes/recallguide/assets/img/drug-image-placeholder.jpg)
![Phenazopyridine Hydrochloride (Phenazopyridine) Tablet [Remedyrepack Inc. ]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b897d574-24f1-4df9-8a13-9ab3592dc544&name=MM2.jpg)
![Phenazopyridine Hydrochloride (Phenazopyridine) Tablet [Remedyrepack Inc. ]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8302b60b-4365-4368-9943-7655abdb7736&name=MM2.jpg)
![Phenazopyridine Hydrochloride (Phenazopyridine) Tablet [Blenheim Pharmacal, Inc.]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0f7c3734-dfa5-7082-e054-00144ff88e88&name=LABEL_PHENAZOPYRIDINEHCLTABS100MG_BPI(10544-115-10)_AMNEAL(65162-517-10)_REV2.jpg)
![Phenazopyridine Hydrochloride (Phenazopyridine) Tablet [A-s Medication Solutions Llc]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=95505b13-c3b7-43cb-a257-bc9c795afe65&name=32b5816d-figure-01.jpg)
![Phenazopyridine Hydrochloride (Phenazopyridine) Tablet [A-s Medication Solutions Llc]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=76eed056-72a1-4a89-ae0e-0e4f52b88667&name=32b5816d-figure-01.jpg)
![Phenazopyridine Hydrochloride (Phenazopyridine) Tablet [Remedyrepack Inc. ]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=55e41839-ca7c-4aac-b29b-2c30679b31f9&name=MM2.jpg)
![Phenazopyridine Hydrochloride (Phenazopyridine) Tablet [Proficient Rx Lp]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9aa1a129-f845-45ab-b01e-4f4f5063d1e1&name=32b5816d-figure-02.jpg)
![Phenazopyridine Hydrochloride (Phenazopyridine) Tablet [Eci Pharmaceuticals, Llc]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=89bb4bd7-6914-4ea8-a2bd-3e70d6f44535&name=32b5816d-figure-01.jpg)
![Phenazopyridine Hydrochloride (Phenazopyridine) Tablet [Amneal Pharmaceuticals]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4f9ddc5b-2cb2-4556-b8ca-32a0283fce79&name=32b5816d-figure-01.jpg)
![Phenazopyridine Hydrochloride (Phenazopyridine) Tablet [Rebel Distributors Corp]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d64a0f0e-1fa4-47cb-a59e-d294e001ba53&name=e039ff7a-285e-4e8e-9584-1642ad5c4c77-02.jpg)
![Phenazopyridine Hydrochloride (Phenazopyridine) Tablet [Medvantx, Inc.]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a63d3ace-768f-4e1b-a5e9-dad1817453b9&name=a63d3ace-768f-4e1b-a5e9-dad1817453b9-02.jpg)
![Phenazopyridine Hydrochloride (Phenazopyridine) Tablet [Unit Dose Services]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=849fa5d5-fc5e-4225-a4fc-e8346ef89369&name=32b5816d-figure-01.jpg)
![Phenazopyridine Hydrochloride (Phenazopyridine) Tablet [Bryant Ranch Prepack]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f00070d6-548d-33d6-4d35-ac564b44a60d&name=label1datamaxfda466.jpg)
![Phenazopyridine Hydrochloride Tablet [American Health Packaging]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b3f9e3f0-01a1-43e8-b44b-91f4f3e2c8cb&name=24220035-37fe-4d90-aae6-f8963fb77fa9-02.jpg)
![Phenazopyridine Hydrochloride (Phenazopyridine) Tablet [Clinical Solutions Wholesale]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bf39cd69-3302-40c7-87f9-3f5e2827c9df&name=Phen200Lab06.jpg)
![Phenazopyridine Hydrochloride (Phenazopyridine) Tablet [Clinical Solutions Wholesale]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2319bd42-5298-4e31-88d2-d8a4beb1befb&name=Phen100Lab3.jpg)
![Phenazopyridine Hydrochloride (Phenazopyridine) Tablet [Liberty Pharmaceuticals, Inc.]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=91202708-1a78-4c87-9d28-1f8f4a77e991&name=phenazopyridine-for-amneal-2.jpg)
![Phenazopyridine Hydrochloride (Phenazopyridine) Tablet [Eci Pharmaceuticals, Llc]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=65346b3f-7a71-4b35-84c8-385ded952867&name=32b5816d-figure-01.jpg)
![Phenazopyridine Hydrochloride (Phenazopyridine) Tablet [Aidarex Pharmaceuticals Llc]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3bea4097-a272-4f5e-8f09-13bb24e905ed&name=phenazopyridine-hcl-100mg-200mg-tab-for-amneal-2.jpg)
![Phenazopyridine Hydrochloride Tablet, Coated [Nationwide Laboratories, Llc]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e2392fa3-69bc-4782-a590-a572cb474e48&name=phenazopyridine-02.jpg)
![Phenazopyridine Hydrochloride (Phenazopyridine) Tablet [Preferred Pharmaceuticals, Inc.]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=480ee010-26f9-479c-b472-91fed589c622&name=dbb8a14f-bfa3-4357-9695-f5fbe5c5f70b-02.jpg)
![Phenazopyridine Hydrochloride Tablet [Direct Rx]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d31ddcfe-08e2-45cc-ae57-2fda7b1edf4b&name=200mglabel.jpg)
![Phenazopyridine Hydrochloride (Phenazopyridine) Tablet [Avkare, Inc.]](http://recallguide.cwdevelopsp.com/wp-content/themes/recallguide/assets/img/drug-image-placeholder.jpg)
![Phenazopyridine Hydrochloride (Phenazopyridine) Tablet [Readymeds]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=32918084-20f5-4050-b94e-09c0dd72e910&name=32b5816d-figure-01.jpg)
![Phenazopyridine Hydrochloride Tablet [Cardinal Health]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a42894b8-ac23-4470-86b6-333f08fd2754&name=image-02.jpg)
![Phenazopyridine Hydrochloride (Phenazopyridine) Tablet [Lake Erie Medical Dba Quality Care Products Llc]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=28c2b732-cdef-4a21-9c51-25c1ffbab488&name=Phenazopyridine100mgAmneal.jpg)
![Phenazopyridine Hydrochloride Tablet [Northwind Pharmaceuticals]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a4481091-d324-4773-8b4b-2de0ffebda53&name=51655-154.jpg)
![Phenazopyridine Hydrochloride (Phenazopyridine) Tablet [Carilion Materials Management]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=43c1b32c-23dc-45c7-afc1-b61599eb7258&name=32b5816d-figure-01.jpg)
![Phenazopyridine Hydrochloride (Phenazopyridine) Tablet [A-s Medication Solutions Llc]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0b56c9ff-69c4-4f51-9d5a-02eb97f17651&name=32b5816d-figure-01.jpg)
![Phenazopyridine Hydrochloride Tablet [Northwind Pharmaceuticals, Llc]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=69a73bf4-f4f8-4928-bc95-8d93f2f9ce6a&name=51655-155-87.jpg)
![Phenazopyridine Hydrochloride (Phenazopyridine) Tablet [Remedyrepack Inc. ]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c0202f13-4ea5-40ce-ab51-7ee97a32e9e2&name=MM2.jpg)
![Phenazopyridine Hydrochloride (Phenazopyridine) Tablet [Remedyrepack Inc. ]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2088d517-8509-4122-9195-cf17a55ad7c0&name=MM2.jpg)
![Phenazopyridine Hydrochloride Tablet [Remedyrepack Inc. ]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4f3f100f-0d80-464b-a7fd-85b7d238f9c3&name=MM2.jpg)
![Phenazopyridine Hydrochloride Tablet [Remedyrepack Inc. ]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=231363cf-b3f9-487c-9270-9c1f9ae9024b&name=MM2.jpg)
Login To Your Free Account